ASAH1 and Farber lipogranulomatosis: Regarding the potential treatment strategies for Farber disease/SMA-PME, enzyme replacement therapy with recombinant acid ceramidase therapy and gene replacement therapy with ASAH1 cDNA are currently being investigated [152,156].